Currently available antiplatelet drugs

Platelet Pathophysiology
Different antiplatelet regiments
• Single antiplatelet therapy
• Not recommended for all apparently healthy individuals above a
moderate level of coronary risk.
• Dual antiplatelet therapy
• CURE study : reduce first primary outcome with no additional
benefit over 12 months
• No studies for long term use of aspirin+clopidogrel despite ESC
recommendations
• No sound evidence yet for dual antiplatelet in DES placement, still
ongoing trial
• New P2Y12 inhibitor (prasugrel & ticagrelor) : further reduction of
primary endpoint
Different antiplatelet regiments
• GPIIb/IIIa
• Marginal in conservative ACS
• Reduced periprocedural thrombotic events (from pooled five RCT)
• These early studies have been challenged  was then without pre-
treatment with thienopyridines  needs further study
TERIMA KASIH